| 000 | 01727 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518093446.0 | ||
| 264 | 0 | _c20210111 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1478-6362 | ||
| 024 | 7 |
_a10.1186/s13075-020-02153-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEinhaus, Jakob | |
| 245 | 0 | 0 |
_aInhibition of effector B cells by ibrutinib in systemic sclerosis. _h[electronic resource] |
| 260 |
_bArthritis research & therapy _c03 2020 |
||
| 300 |
_a66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenine _xanalogs & derivatives |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAgammaglobulinaemia Tyrosine Kinase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aB-Lymphocytes _xcytology |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNF-kappa B _xmetabolism |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aPiperidines _xpharmacology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xdrug therapy |
| 700 | 1 | _aPecher, Ann-Christin | |
| 700 | 1 | _aAsteriti, Elisa | |
| 700 | 1 | _aSchmid, Hannes | |
| 700 | 1 | _aSecker, Kathy-Ann | |
| 700 | 1 | _aDuerr-Stoerzer, Silke | |
| 700 | 1 | _aKeppeler, Hildegard | |
| 700 | 1 | _aKlein, Reinhild | |
| 700 | 1 | _aSchneidawind, Corina | |
| 700 | 1 | _aHenes, Joerg | |
| 700 | 1 | _aSchneidawind, Dominik | |
| 773 | 0 |
_tArthritis research & therapy _gvol. 22 _gno. 1 _gp. 66 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s13075-020-02153-8 _zAvailable from publisher's website |
| 999 |
_c30796473 _d30796473 |
||